Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster Sells 50,477 Shares

Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $17.81, for a total value of $898,995.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kurt Von Emster also recently made the following trade(s):

  • On Thursday, August 17th, Kurt Von Emster sold 34,141 shares of Crispr Theraptc stock. The stock was sold at an average price of $19.06, for a total value of $650,727.46.
  • On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of Crispr Theraptc stock. The stock was sold at an average price of $19.59, for a total value of $1,088,596.71.
  • On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of Crispr Theraptc stock. The stock was sold at an average price of $18.63, for a total value of $660,861.99.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.51, for a total value of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.63, for a total value of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.60, for a total value of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.84, for a total value of $1,176,425.56.
  • On Wednesday, July 12th, Kurt Von Emster sold 31,992 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.56, for a total value of $529,787.52.
  • On Wednesday, July 5th, Kurt Von Emster sold 4,254 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.26, for a total value of $69,170.04.
  • On Thursday, June 29th, Kurt Von Emster sold 43,202 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.90, for a total value of $730,113.80.

Crispr Theraptc (NASDAQ CRSP) traded down 0.43% during trading on Friday, hitting $18.34. The stock had a trading volume of 60,044 shares. Crispr Theraptc has a 52 week low of $11.63 and a 52 week high of $25.00. The company’s market cap is $744.44 million. The company has a 50-day moving average of $17.38 and a 200 day moving average of $17.51.

Crispr Theraptc (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company’s revenue was up 350.0% on a year-over-year basis. On average, equities research analysts anticipate that Crispr Theraptc will post ($2.43) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/08/19/kurt-von-emster-sells-50477-shares-of-crispr-theraptc-nasdaqcrsp-stock-updated.html.

A number of large investors have recently added to or reduced their stakes in the company. IHT Wealth Management LLC acquired a new stake in Crispr Theraptc during the first quarter valued at approximately $110,000. Wells Fargo & Company MN boosted its stake in Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares in the last quarter. ARK Investment Management LLC acquired a new stake in Crispr Theraptc during the second quarter valued at approximately $206,000. Vanguard Group Inc. acquired a new stake in Crispr Theraptc during the second quarter valued at approximately $273,000. Finally, Monashee Investment Management LLC boosted its stake in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares in the last quarter. 24.08% of the stock is owned by institutional investors and hedge funds.

Several research firms have recently issued reports on CRSP. Cann began coverage on Crispr Theraptc in a research report on Monday, July 17th. They set a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research report on Tuesday, July 18th. SunTrust Banks, Inc. began coverage on Crispr Theraptc in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 target price for the company. Finally, Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a research report on Monday, August 14th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $21.92.

Crispr Theraptc Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

What are top analysts saying about Crispr Theraptc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Crispr Theraptc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit